Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
New England Journal of MedicinePublished 10 January 2007Open access
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe
Citations5,710
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Abstract
Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
CA A Cancer Journal for CliniciansGlobal cancer statistics
54,961 Citations2011Ahmedin Jemal, Freddie Bray +3 more
A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
CA A Cancer Journal for CliniciansGlobal Cancer Statistics, 2002
18,390 Citations2005Donald Maxwell Parkin, Freddie Bray +2 more
There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
JNCI Journal of the National Cancer InstituteNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
15,642 Citations2000Patrick Therasse, Susan G. Arbuck +9 more
A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal of Clinical OncologyThe Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
6,031 Citations1993David Cella, David S. Tulsky +8 more
The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change.
Analysis of Survival Data
5,999 Citations2018D. R. Cox, David Oakes
NatureThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
5,203 Citations1999Patrick H. Maxwell, Michael S. Wiesener +8 more
It is indicated that the interaction between HIF-1 and pVHL is iron dependent, and that it is necessary for the oxygen-dependent degradation of HIF α-subunits, which may underlie the angiogenic phenotype of VHL-associated tumours.
Wiley series in probability and statisticsApplied Longitudinal Analysis
4,568 Citations2011Garrett M. Fitzmaurice, Nan M. Laird +1 more
New England Journal of MedicineA Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
2,696 Citations2003James Chih‐Hsin Yang, Leah Haworth +7 more
Bvacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer, and this trial was stopped after the interim analysis met the criteria for early stopping.
New England Journal of MedicineRenal-Cell Carcinoma
2,228 Citations1996Robert J. Motzer, Neil H. Bander +1 more
PubMedIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
1,973 Citations2003Dirk B. Mendel, Alexander Laird +21 more
The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Nature GeneticsMutations of the VHL tumour suppressor gene in renal carcinoma
1,741 Citations1994James R. Gnarra, Kálmán Tory +22 more
The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.
Journal of Clinical OncologyActivity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
1,632 Citations2005Robert J. Motzer, M. Dror Michaelson +13 more
The genetics of RCC and these promising clinical results support the hypothesis that VEGF and PDGF receptor-mediated signaling is an effective therapeutic target in RCC, as second-line therapy in a setting where no effective systemic therapy is presently recognized.
Journal of Clinical OncologyInterferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma
1,505 Citations2002Robert J. Motzer, Jennifer Bacik +3 more
JAMASunitinib in Patients With Metastatic Renal Cell Carcinoma
1,224 Citations2006Robert J. Motzer, Brian I. Rini +13 more
New England Journal of MedicineRecombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
965 Citations1998Sylvie Négrier, Bernard Escudier +10 more
A multicenter, randomized trial to determine the effect of each cytokine independently and in combination, and to identify patients who are best suited for this treatment of metastatic renal-cell carcinoma.
Proceedings of the National Academy of SciencesNegative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
897 Citations1996Othon Iliopoulos, Andrew P. Levy +3 more
Renal carcinoma cells lacking wild-type pVHL were found to produce mRNAs encoding VEGF/VPF, the glucose transporter GLUT1, and the platelet-derived growth factor B chain under both normoxic and hypoxic conditions, thus restoring their previously described hypoxia-inducible profile.
BloodSU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
857 Citations2003Anne-Marie O'Farrell, Tinya J. Abrams +13 more
The in vivo efficacy of SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the subcutaneous tumor xenograft model and prolongs survival in the bone marrow engraftment model, suggesting that further exploration of SU 11248 activity in AML patients is warranted.
Journal of Clinical OncologyRandomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
819 Citations2004David F. McDermott, Meredith M. Regan +16 more
This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.
Journal of Clinical OncologyRandomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
781 Citations2003James Chih‐Hsin Yang, Richard M. Sherry +11 more
IL-2 was more clinically active at maximal doses, although this did not produce an overall survival benefit, and the immunological factors which constrain the curative potential of IL-2 to only a small percentage of patients need to be further elucidated.
Urologic Clinics of North AmericaSurveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
778 Citations2003Nicolette Janzen, Hyung L. Kim +2 more
Proposed surveillance protocols attempt to provide a rational approach to identifying treatable recurrences while minimizing unnecessary examinations and patient anxiety and strict adherence to follow-up guidelines may not be appropriate for all patients.
PubMedSU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
639 Citations2003Tinya J. Abrams, Leslie B. Lee +3 more
It is suggested that SU11248 may have clinical potential in the treatment of SCLC via direct antitumor activity mediated via KIT as well as tumor angiogenesis via vascular endothelial growth factor receptor FLK1/KDR and PDGFRbeta.
Journal of Clinical OncologyInterferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma
606 Citations2002Robert J. Motzer
Progression-free and overall survival with interferon-alpha treatment can be compared with new therapies in phase II and III clinical investigations and the prognostic model is suitable for risk stratification of phase III trials using interferons-alpha as the comparative treatment arm.
The Journal of UrologySYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
605 Citations2000Robert J. Motzer, Paul Russo
No chemotherapy agent has produced response rates that justify its use as a single agent and metastatic renal cell carcinoma remains highly resistant to systemic therapy.
Cochrane Database of Systematic ReviewsImmunotherapy for advanced renal cell cancer
593 Citations2004Chris Coppin, Franz Porzsolt +4 more
Interferon-alpha provides a modest survival benefit compared to other commonly used treatments and should be considered for the control arm of future studies of systemic agents.
Journal of Clinical OncologyValidation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
571 Citations2005Tarek Mekhail, Rony M. Abou-Jawde +5 more
These data validate the model described by Motzer et al for survival in patients with previously untreated metastatic renal cell carcinoma and identify additional independent prognostic factors, which were prior radiotherapy and sites of metastasis.
Evaluation & the Health ProfessionsGeneral Population and Cancer Patient Norms for the Functional Assessment of Cancer Therapy-General (FACT-G)
535 Citations2005Penny S. Brucker, Kathleen J. Yost +3 more
Normative data for the FACT-G are presented for two reference groups: a sample of the general U.S. adult population and a large, heterogeneous sample of adult patients with cancer.
The LancetInterferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial
519 Citations1999Griffiths, Gareth
Combination regimens of biological therapy and chemotherapy should now be compared with interferon-alpha monotherapy in randomised controlled trials.
Journal of Clinical OncologyProspective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer
443 Citations1999Seppo Pyrhönen, Eeva Salminen +8 more
The combination of IFNalpha2a plus VLB is superior to VLB alone in the treatment of patients with locally advanced or metastatic renal cell carcinoma, and this is the first study to demonstrate that survival can be prolonged by using IFN alpha2a for these patients.
PubMedLong-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
441 Citations2000Richard I. Fisher, Steven A. Rosenberg +1 more
With prolonged follow-up, treatment with high-dose recombinant IL-2 remains extremely effective for a subset of patients with metastatic renal cell carcinoma.
Cancer Biology & TherapyRhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
385 Citations2003David J. Kwiatkowski
Developments in Drosophila provide enhanced understanding of this signaling pathway and fundamental insights into the pathogenesis of tuberous sclerosis, and open the possibility of treatment for hamartomas by several pharmacologic approaches.
Journal of Clinical OncologyRandomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)
350 Citations2005Bernard Escudier, Cezary Szczylik +5 more
This Phase III, double-blind trial to assess overall survival (OS) in pts with confirmed advanced clear-cell RCC randomized to BAY vs best supportive care (BSC) and results of a planned analysis on the secondary endpoint, progression free survival (PFS) will be presented in this report.
Journal of Clinical OncologyPhase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma
269 Citations2000Robert J. Motzer, Barbara A. Murphy +9 more
Responsibility proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC, and 13-cis-retinoic acid may lengthen response toIFNalpha1a-sensitive tumors.
World Journal of UrologyNovel approaches in the therapy of metastatic renal cell carcinoma
226 Citations2005John S. Lam, John T. Leppert +2 more
An update on current therapeutic approaches and targeted molecular therapy for metastatic RCC is provided to provide an update on the development of new therapies based on molecular targeting.
CancerTrends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
200 Citations1998Udai S. Kammula, Donald E. White +1 more
Administration of recombinant high dose interleukin‐2 (IL‐2) can mediate tumor regression in patients with metastatic melanoma and renal carcinoma.
The Journal of UrologyOverproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.
196 Citations2003Xinni Na, Guan Wu +4 more
The findings indicate that VHL gene alterations and HIF-1 alpha protein expression correlate with a significant increase in VEGF production by RCC, which is associated with a more aggressive tumor phenotype.
Journal of Clinical OncologyLong-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.
160 Citations1996G. Fyfe, Richard I. Fisher +4 more
PubMedDevelopment and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
100 Citations2006David Cella, Susan Yount +8 more
The FK SI-15 and FKSI-10 are reliable and valid symptom indices for evaluating kidney cancer patients and show high internal consistency and correlations between both the physical and functional well being domains of the FACT-G were high.
Journal of Clinical OncologyDo cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial
89 Citations2005Sylvie Négrier, David Pérol +8 more
The primary endpoint was overall survival (OS), and the planned sample size was 456 pts based on a minimum expected difference of 10% in OS at 2 years with 5% α error and 80% power.
Doing Data Analysis with the Multilevel Model for Change
32 Citations2003J. David Singer, John B. Willett